Recent studies from the United Kingdom and Australia have shown that multigene testing (BRCA1, BRCA2 and PALB2, and BRCA1 and BRCA2, respectively) for all breast cancer patients would be cost-effective when compared with current eligibility criteria based on personal and family-history testing [15, 16]. This evidence concerns the gene PALB2 and breast carcinoma.